Genmab A/S (NASDAQ:GMAB) Receives Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Genmab A/S (NASDAQ:GMAB) in a research note published on Wednesday,Benzinga reports. HC Wainwright currently has a $40.00 target price on the stock.

Several other research firms have also recently commented on GMAB. Truist Financial lifted their price target on Genmab A/S from $45.00 to $46.00 and gave the company a “buy” rating in a report on Tuesday, July 8th. Guggenheim upgraded Genmab A/S from a “neutral” rating to a “buy” rating and set a $43.00 price target for the company in a report on Tuesday, September 23rd. Wall Street Zen upgraded Genmab A/S from a “buy” rating to a “strong-buy” rating in a report on Friday, September 26th. Zacks Research upgraded Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 2nd. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Genmab A/S in a report on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Genmab A/S currently has a consensus rating of “Moderate Buy” and a consensus price target of $40.80.

Genmab A/S Trading Down 0.1%

Genmab A/S stock opened at $32.72 on Wednesday. The stock has a market cap of $21.01 billion, a PE ratio of 16.44, a P/E/G ratio of 1.85 and a beta of 0.98. The stock has a 50-day moving average price of $27.51 and a 200 day moving average price of $23.13. Genmab A/S has a 52 week low of $17.24 and a 52 week high of $33.63.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.54 EPS for the quarter, topping analysts’ consensus estimates of $0.39 by $0.15. The firm had revenue of $925.00 million during the quarter, compared to analysts’ expectations of $5.77 billion. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%. Genmab A/S has set its FY 2025 guidance at EPS. On average, equities analysts predict that Genmab A/S will post 1.45 EPS for the current year.

Hedge Funds Weigh In On Genmab A/S

Several hedge funds and other institutional investors have recently modified their holdings of the company. Orbis Allan Gray Ltd lifted its stake in shares of Genmab A/S by 38.7% in the 2nd quarter. Orbis Allan Gray Ltd now owns 7,920,400 shares of the company’s stock valued at $163,635,000 after purchasing an additional 2,209,659 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its position in Genmab A/S by 152.3% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 3,454,378 shares of the company’s stock worth $71,367,000 after acquiring an additional 2,084,966 shares in the last quarter. First Trust Advisors LP lifted its position in Genmab A/S by 3.5% during the 2nd quarter. First Trust Advisors LP now owns 1,770,310 shares of the company’s stock worth $36,575,000 after acquiring an additional 60,504 shares in the last quarter. Brandywine Global Investment Management LLC lifted its position in Genmab A/S by 1.6% during the 2nd quarter. Brandywine Global Investment Management LLC now owns 1,744,769 shares of the company’s stock worth $36,047,000 after acquiring an additional 27,372 shares in the last quarter. Finally, Cubist Systematic Strategies LLC lifted its position in Genmab A/S by 112.4% during the 1st quarter. Cubist Systematic Strategies LLC now owns 1,258,143 shares of the company’s stock worth $24,634,000 after acquiring an additional 665,893 shares in the last quarter. 7.07% of the stock is owned by institutional investors and hedge funds.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.